MWM
VIRX

MBE Wealth Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

MBE Wealth Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5
Closed – – 559
2020
Q1 		$0 Buy
+5
New +$109 ﹤0.01% 584

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

MBE Wealth Management's VIRX Position: Q2 2020 in Review

MBE Wealth Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2020, closing a stake of 5 shares.

MBE Wealth Management first reported a position in VIRX in Q1 2020 and held it in 1 quarter. The position peaked at $0 in Q1 2020. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2020.

  • MBE Wealth Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • MBE Wealth Management sold 5 Viracta Therapeutics, Inc. Common Stock shares in Q2 2020.
  • MBE Wealth Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • MBE Wealth Management's Viracta Therapeutics, Inc. Common Stock position peaked at $0 in Q1 2020.
  • 41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2020.

Based on MBE Wealth Management's 13F filing for Q2 2020, filed 14 Aug 2020.